<DOC>
	<DOC>NCT02995239</DOC>
	<brief_summary>To compare the pharmacokinetics after administration of different formulation of CJ-12420</brief_summary>
	<brief_title>A Study to Compare the Pharmacokinetic Characteristics of CJ-12420</brief_title>
	<detailed_description>The purpose of this study is to compare the pharmacokinetics after a single dose administration of CJ-12420 formulation 1 and formulation 2.</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<criteria>Healthy male aged 19 to 45 years at the screening Subject who is over 50kg with BMI between 19 kg/m2 to 28 kg/m2 (inclusive) Subject who fully understood after being informed detailed description of clinical trial, written informed consent voluntarily to observe the precautions. Subject who fall under the criteria below in laboratory test. AST, ALT, ALP, GGT, total bilirubin, BUN, creatinine &gt; UNL x 1.5 Subject who with low blood pressure with clinical significance at screening test. (systolic blood pressure is less than 90 mmHg or over 140 mmHg, and diastolic blood pressure is less than 50 mmHg or over 90 mmHg) Subject who has a medical history of symptomatic GERD, erosive esophagitis or duodenal ulcer, gastric ulcer, barrett's esophagus or zollingerellison syndrome.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>